» Articles » PMID: 30402324

Injectable Chemotherapy Downstaged Oral Squamous Cell Carcinoma from Nonresectable to Resectable in a Rescue Dog: Diagnosis, Treatment, and Outcome

Overview
Publisher Wiley
Date 2018 Nov 8
PMID 30402324
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This case report documents the diagnosis, treatment, and outcome of a nonresectable oral squamous cell carcinoma in a dog with initial poor prognosis. An approximately 4-year-old female Staffordshire Bull Terrier presented with a large mass on the front of lower jaw which was diagnosed as oral papillary squamous cell carcinoma by histopathology. CT scans revealed invasion of the cancer to the frenulum of the tongue. The mass was inoperable due to location, expansiveness, and metastatic lymph nodes. The dog received 4 treatments of intralesional hyaluronan-platinum conjugates (HylaPlat™, HylaPharm LLC, Lawrence, Kansas) at 3-week intervals. Clinical chemistry and complete blood count were performed one week after each treatment and results were within normal limits. Complications included bleeding due to tumor tissue sloughing, as well as a single seizure due to unknown causes. Upon completion of chemotherapy, CT showed that the mass had regressed and was no longer invading the lingual frenulum, and multiple lymph nodes were free of metastasis. The mass thus became resectable and the dog successfully underwent rostral bilateral mandibulectomy. Over one year after chemotherapy and surgery, the cancer remains in complete remission.

Citing Articles

Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs.

Ambrosio N, Voci S, Gagliardi A, Palma E, Fresta M, Cosco D J Funct Biomater. 2022; 13(3).

PMID: 35997454 PMC: 9397006. DOI: 10.3390/jfb13030116.


Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent.

Groer C, Zhang T, Lu R, Cai S, Mull D, Huang A Mol Pharm. 2020; 17(11):4334-4345.

PMID: 32975949 PMC: 8200829. DOI: 10.1021/acs.molpharmaceut.0c00781.

References
1.
Cai S, Zhang T, Forrest W, Yang Q, Groer C, Mohr E . Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors. Am J Vet Res. 2016; 77(9):1005-16. PMC: 5008241. DOI: 10.2460/ajvr.77.9.1005. View

2.
Knapp D, Richardson R, Bonney P, Hahn K . Cisplatin therapy in 41 dogs with malignant tumors. J Vet Intern Med. 1988; 2(1):41-6. DOI: 10.1111/j.1939-1676.1988.tb01976.x. View

3.
Cai S, Xie Y, Davies N, Cohen M, Forrest M . Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci. 2009; 99(6):2664-71. PMC: 3102643. DOI: 10.1002/jps.22016. View

4.
Ishiguro S, Cai S, Uppalapati D, Turner K, Zhang T, Forrest W . Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice. Pharm Res. 2016; 33(10):2517-29. PMC: 5007205. DOI: 10.1007/s11095-016-1976-3. View

5.
Cohen S, Mukerji R, Cai S, Damjanov I, Forrest M, Cohen M . Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg. 2011; 202(6):646-52. PMC: 5198781. DOI: 10.1016/j.amjsurg.2011.06.027. View